How changes in RNA-binding proteins affect the blood-brain barrier and Alzheimer's disease
Contributions of Endothelial RNA-binding Protein Dysregulation to Blood Brain Barrier Defects and Neurodegenerative Disease
['FUNDING_R01'] · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · NIH-10611787
This study is looking at how a protein called TDP-43 affects the blood-brain barrier, which is important for brain health, to help us understand more about Alzheimer's and similar conditions as we age.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT (nih funded) |
| Locations | 1 site (FARMINGTON, UNITED STATES) |
| Trial ID | NIH-10611787 on ClinicalTrials.gov |
What this research studies
This research investigates the role of RNA-binding proteins, particularly TDP-43, in the functioning of the blood-brain barrier (BBB) and its implications for Alzheimer's disease and related dementias. By examining how splicing dysregulation in endothelial cells contributes to BBB defects, the study aims to uncover new mechanisms of cognitive decline associated with aging and neurodegenerative diseases. The researchers utilize advanced techniques, including CRISPR screening and analysis of human brain tissues, to explore the relationship between TDP-43 levels and BBB integrity. This approach may lead to a better understanding of how these molecular changes influence disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those experiencing cognitive decline.
Not a fit: Patients with other forms of dementia not related to Alzheimer's or those without cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies aimed at preserving blood-brain barrier function and slowing the progression of Alzheimer's disease.
How similar studies have performed: While the specific focus on endothelial RNA-binding protein dysregulation in the context of Alzheimer's is novel, related research has shown that targeting splicing mechanisms can have significant implications for neurodegenerative diseases.
Where this research is happening
FARMINGTON, UNITED STATES
- UNIVERSITY OF CONNECTICUT SCH OF MED/DNT — FARMINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MURPHY, PATRICK ANDRIES — UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- Study coordinator: MURPHY, PATRICK ANDRIES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia